Redcare Pharmacy stock: Rx growth supports second profitable quarter

Published on 11/03/2026 at 18:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Redcare Pharmacy stock is being driven by strong German prescription sales and a second consecutive profitable quarter. Management kept its upgraded 2026 targets.

Growth strengthens the profitability path

German prescription revenue remained the main growth engine in the third quarter.
Management maintained its upgraded 2026 targets and expects positive free cash flow in 2027.
The next scheduled company update is the 2026 trading statement on January 11, 2027.

Redcare Pharmacy, NL0012044747, Illustration mit AI erstellt.

Redcare Pharmacy delivered another profitable quarter on October 29, with German prescription sales again leading growth. The company confirmed its upgraded 2026 targets in its October 29 results release.

Prescription sales lead expansion

Group revenue rose 18 percent year over year to 847 million euros in the third quarter. Prescription revenue increased 31 percent to 358 million euros, while German prescription revenue jumped 56 percent to 197 million euros. Non-prescription revenue grew 9 percent to 489 million euros.

The active customer base reached 15.2 million at the end of September, an increase of 0.5 million during the quarter. The company said German prescription activity added 123,000 active customers in the period, nearly twice the increase recorded in the second quarter.

Profitability moves further forward

Adjusted EBITDA increased 68 percent year over year to 28.7 million euros, lifting the margin to 3.4 percent from 2.4 percent. DACH adjusted EBITDA reached 29 million euros, and the segment margin improved to 4.2 percent from 3.0 percent.

Net income was positive at 1 million euros, marking a second consecutive profitable quarter. Free cash flow reached 15 million euros in the quarter, while nine-month revenue rose 19 percent to 2.55 billion euros.

Targets remain unchanged

Management continues to target total revenue growth of 16 to 18 percent, non-prescription growth of 10 to 12 percent, German prescription revenue of 730 million to 760 million euros and an adjusted EBITDA margin of 2.5 to 3.0 percent. Redcare also expects positive free cash flow in 2027.

Compared with 75.53 euros in the company's own report at 11:36 CET on Tuesday, November 3, Redcare Pharmacy stock traded at 74.15 euros on Lang & Schwarz at 18:38 CET the same day, down 1.83 percent. The quote was 0.20 percent above the Xetra close of 74.00 euros on Tuesday, November 3. The real-time quote of Redcare Pharmacy stock provides the latest trading view.